PACB241018P3000
- 0.95
- +0.40+72.73%
Pacific Biosciences of California Newsroom
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
Pacific Biosciences Analyst Ratings
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $7
Pacific Biosciences (PACB) Receives a Buy From Scotiabank
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2.5
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
Pacific Biosciences Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pacific Biosciences, Maintains $3.5 Price Target
Piper Sandler Keeps Their Hold Rating on Pacific Biosciences (PACB)
Pacific Biosciences Price Target Cut to $3.00/Share From $3.50 by Canaccord Genuity
Pacific Biosciences Analyst Ratings
Critical Insights From Pacific Biosciences Analyst Ratings: What You Need To Know
Pacific Biosciences Analyst Ratings
Jefferies Initiates Coverage On Pacific Biosciences With Buy Rating, Announces Price Target of $4
Damo: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $10.00 to $4.00.
Pacific Biosciences Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $4